Quantum Genesis AI Corp. (OTC: QGAI), a technology company involved in artificial intelligence, computational modeling, and scientific innovation, announced today that it has issued a statement concerning the Caveat Emptor designation placed on its securities by OTC Markets Group, Inc. on February 12, 2026. The company has been actively seeking clarification from OTC Markets regarding the basis for the designation, which OTC Markets has attributed to a "public interest concern."
Since the designation was applied, Quantum Genesis AI has made multiple attempts to communicate with OTC Markets to understand the specific reasons behind the action and to determine the necessary steps to resolve the matter. OTC Markets recently informed the company that it may formally request a review of the designation beginning March 13, 2026. Quantum Genesis AI intends to engage with OTC Markets at the earliest available opportunity to initiate that review process.
"We take this matter seriously and are committed to working constructively with OTC Markets to better understand the basis for the designation," said Naveen Kulkarni, Chief Executive Officer of Quantum Genesis AI Corp. "Our objective is to obtain clarity regarding the matter and to take any appropriate steps necessary as we move through the review process."
The Caveat Emptor designation is a warning to investors that there may be a public interest concern associated with the company's securities. This designation can affect the trading of the company's stock and investor confidence. For Quantum Genesis AI, addressing this designation is critical to maintaining its reputation and ensuring continued access to capital markets.
The company remains committed to transparency with its shareholders and the broader investment community. Quantum Genesis AI intends to continue cooperating with OTC Markets and will provide updates as additional information becomes available. For more information and updates, please visit www.qgaicorp.com and the Company’s profile at www.otcmarkets.com/stock/QGAI.
The implications of this announcement are significant for investors and the company alike. The Caveat Emptor designation can lead to reduced liquidity and increased scrutiny from regulators. Quantum Genesis AI's proactive approach in seeking a review demonstrates its commitment to resolving the issue and restoring normal trading conditions. The outcome of the review process could have a material impact on the company's stock performance and its ability to raise capital.
Quantum Genesis AI Corp. is focused on advancing next-generation technologies at the intersection of artificial intelligence, computational modeling, and scientific innovation. The company’s strategy includes leveraging advanced data-driven tools to support research, discovery, and technology development across emerging sectors while maintaining a commitment to transparency and responsible corporate governance.
As the review process unfolds, stakeholders will be watching closely to see how the company navigates this challenge and what steps it takes to address the concerns raised by OTC Markets. The company's ability to effectively communicate and cooperate with regulators will be key to resolving the designation and moving forward.
